人工晶状体植入术后化脓性眼内炎治疗的临床分析

目的分析总结人工晶状体植入术后化脓性眼内炎的临床特征及治疗效果。方法2001年2月～2004年4月,我院收治此类患者7例(7只眼),分别于人工晶状体植入术后1～12天发生化脓性眼内炎。感染后视力：光感～手动／30cm。治疗方法：2只眼行玻璃体腔药物注射;4只眼行玻璃体切除联合玻璃体腔药物注射;1只眼行眼内容剜出术。结果术后随访1～36个月,6只眼眼内炎症控制,视力分别为0、02、0．4、0．6、0．8、0．8,其中1只眼出现角膜内皮功能失代偿。结论人工晶状体植入术后突然发生的术眼疼痛是化脓性眼内炎早期重要特征之一。玻璃体腔注射联合玻璃体切除术是人工晶状体植入术后化脓性眼内炎安全、有效的治疗方法。     

玻璃体切割治疗白内障术后眼内炎疗效观察

目的探讨白内障术后眼内炎的临床特点及治疗方法。方法分析5例（5眼）白内障术后眼内炎的治疗方法。结果5眼白内障术后眼内炎经玻璃体切割术，并辅以全身及局部抗生素治疗，眼内炎症得到控制，视力得到不同程度改善。结论白内障术后眼内炎是白内障手术的严重并发症，玻璃体切割术联合玻璃体腔内注药是一种有效的治疗方法，把握手术时机可以最大限度挽救患者视力，保全眼球。     

玻璃体切割联合玻璃体腔注药治疗感染性眼内炎的临床分析

目的 评估玻璃体切割联合玻璃体腔注药术对感染性眼内炎的治疗效果。方法 对感染性眼内炎患者18例(18只眼)施行玻璃体切割联合玻璃体腔注药术，并观察其疗效。结果 术后矫正视力提高11只眼，不变2只眼，降低4只眼。2例眼内感染未能控制，16例患者均炎症消退，角膜透明，前房清，眼球无萎缩。结论 玻璃体切割联合玻璃体腔注药术是治疗感染性眼内炎的有效手段。     

玻璃体切割联合玻璃体腔注药治疗眼内炎28例

目的：评价玻璃体切割联合玻璃体腔注药治疗严重眼内炎的临床应用价值方法：回顾性分析经28例28眼严重眼内炎行平坦部玻璃体切割术联合玻璃体注药,眼内异物出,配合全身及局部应用抗生素、皮质类固醇药物治疗的临床资料。结果：随访6～12mo,28例28眼眼内感染全部控制。26眼视力不同程度的提高,2眼眼球萎缩。结论：玻璃体切割联合玻璃体腔注药是治疗化脓性眼内炎最有效方法。     

玻璃体切除术治疗化脓性眼内炎

目的 探讨玻璃体切除术治疗化脓性眼内炎的临床价值。方法 对24例（24眼）化脓性眼内炎行玻璃体切除、巩膜环扎及联合晶状体切除、眼内异物摘出、眼内充填术、配合全身及局部应用抗生素，皮质类固醇治疗。术后随访6～18月。结果 24例眼内炎感染全部得到控制。18例术后视力有不同程度提高，4例术后视力无变化，2例眼球萎缩。结论 玻璃体切除联合抗生素应用是治疗化脓性眼内炎的有效方法。     

玻璃体手术治疗化脓性眼内炎

目的：观察玻璃体切割手术联合眼内灌注抗生素治疗化脓性眼内炎的临床疗效。方法：回顾性分析68例68眼化脓性眼内炎行玻璃体切割手术联合灌注抗生素治疗效果,分析对比眼内炎的治疗方法及术中注意事项。结果：68例68眼内炎症全部控制,61眼眼球保存并且视力有不同程度的提高,视力在0．05以上者占48．5％,7眼眼球萎缩。结论：玻璃体切割联合眼内灌注抗生素是治疗化脓性眼内炎最理想的方法,及时手术,术中精心操作是取得良好疗效的关键。     

玻璃体切割联合眼内注药治疗外源性真菌性眼内炎的远期疗效分析

目的 观察玻璃体切割及眼内注药治疗外源性真菌性眼内炎的远期疗效。方法 对11例(11只眼)确诊为真菌性眼内炎者采取玻璃体切割联合玻璃体腔注药治疗，随访1～3年，观察其治疗效果。结果 11例中，有5只眼保存有用视力，眼前手动2只眼，光感1只眼，眼球萎缩2只眼，1只眼因术后疼痛行眼球摘除。结论 真菌性眼内炎的预后不佳，早期行玻璃体切割联合眼内注药，可拯救部分视力。     

玻璃体切除联合玻璃体腔注药治疗外伤所致眼内炎

目的:探讨玻璃体切除联合玻璃体腔注射抗生素治疗外伤所致眼内炎的疗效。方法:对11例(11眼)外伤所致眼内炎进行玻璃体切除以及玻璃体腔注射抗生素,合并晶状体损伤、球内异物、视网膜裂孔及视网膜脱离的病例进行晶状体切除,球内异物取出,激光光凝及硅油或C3F8充填术。随访3mo～2a。结果:11眼(100%)控制了炎症,保留了眼球。6眼(55%)视力比术前提高,3眼(27%)视力无变化,2眼(18%)视力比术前下降。结论:玻璃体切除联合玻璃体腔注射抗生素能够有效治疗外伤所致眼内炎。     

外因性化脓性眼内炎的病因和临床治疗分析

目的分析外因性化脓性眼内炎的病因构成及玻璃体注药和玻璃体切割术治疗的临床效果。方法对外因性化脓性眼内炎患者27例（28眼）的临床资料进行回顾性分析，并进行随访。结果眼球穿孔伤导致的眼内炎13眼，与白内障手术相关的眼内炎12眼，青光眼手术晚期滤泡感染2眼，玻璃体切割术后感染1眼。经玻璃体注药或联合玻璃体切割术治疗后，炎症控制眼球外形结构完整20眼，占71．43％，其中功能成功（视力≥0．02）18眼，占64．29％，均达脱盲（视力≥0．05）标准。结论眼球穿孔伤和白内障手术是目前导致外因性眼内炎的最主要原因，尽早行玻璃体注药或联合玻璃体切割术是治疗化脓性眼内炎的有效方法。     

人工晶状体植入术后感染性眼内炎的治疗

目的 探讨白内障摘出联合人工晶状体植入术后感染性眼内炎的治疗效果。方法 对12例白内障摘出联合人工晶状体植入术后并发感染性眼内炎患者进行前房冲洗、玻璃体切除和玻璃体腔内注药及其它综合治疗。结果 11眼眼内炎症得到控制，1眼因炎症不能控制而行眼内容摘除。8眼视力有不同程度提高。结论 目前临床上对白内障摘出术后，感染性眼内炎的治疗首选方法是前房冲洗和早期玻璃体切除联合玻璃体腔内注入适量广谱抗生素，术后配合中西药物综合治疗。     

Strabisme Alternant - Etude clinique - traitement

The author defines motor and sensory alternation: the term alternation should not be used in isolation, it should always be accompanied by the name of the parameter concerned. Sensory alternation is always found together with motor alternation but the reverse is not true.The examining criteria for a diagnosis of sensory alternation are given, sensory alternation must not be confused with alternating inhibition. Working from clinical observations of cases of motor alternating strabismus, the author selects 2 types of binocular sensory relations which allow one to differentiate between:- cases of primary alternating strabismus- cases of secondary alternating strabismusThese forms will develop in different ways; in both cases a cure is possible providing that the right treatment is prescribed and once prescribed carefully followed, etc. It is always a case of serious forms of strabismus whose developmental period is spread over several years.According to the authors, the frequency of cases of true primary strabismus is from 1–3%, the frequency of cases of secondary alternating strabismus varies according to the type of therapy practised on cases of monocular strabismus with amblyopia. These latter will become cases of alternating strabismus under the influence of certain types of therapy carried out over several years (penalization, rocking, alternated occlusion, etc...).Experimental data on kittens confirm clinical data; kittens placed in abnormal environments during the sensitive period will show modification in the distribution of cortical cells and the absence of binocular cells (either because the excitation of the two eyes was not simultaneous, or not identical: artificial strabismus, occlusion, opaque glasses). This disturbances become irreversible after a certain period of exposure (a function of age, length of exposure, etc...).It is thus necessary to bear in mind: 1) the iatrogenic risks of certain orthoptic treatments, 2) the necessity for a binocular form of treatment as soon as possible, as once a certain stage is passed, cortical plasticity diminishes and the elaboration of normal binocular relations becomes impossible.

---

     

Effects of Adenosine Agonists on Intraocular Pressure and Aqueous Humor Dynamics in Cynomolgus Monkeys

The effects of single or multiple topical doses of the relatively selective A₁adenosine receptor agonists (R)-phenylisopropyladenosine (R-PIA) and N⁶-cyclohexyladenosine (CHA) on intraocular pressure (IOP), aqueous humor flow (AHF) and outflow facility were investigated in ocular normotensive cynomolgus monkeys. IOP and AHF were determined, under ketamine anesthesia, by Goldmann applanation tonometry and fluorophotometry, respectively. Total outflow facility was determined by anterior chamber perfusion under pentobarbital anesthesia. A single unilateral topical application of R-PIA (20–250 μg) or CHA (20–500 μg) produced ocular hypertension (maximum rise=4.9 or 3.5 mmHg) within 30 min, followed by ocular hypotension (maximum fall=2.1 or 3.6 mmHg) from 2–6 hr. The relatively selective adenosine A₂antagonist 3,7-dimethyl-1-propargylxanthine (DMPX, 320 μg) inhibited the early hypertension, without influencing the hypotension. Neither 100 μg R-PIA nor 500 μg CHA clearly altered AHF. Total outflow facility was increased by 71% 3 hr after 100 μg R-PIA. In conclusion, the early ocular hypertension produced by topical adenosine agonists in cynomolgus monkeys is associated with the activation of adenosine A₂receptors, while the subsequent hypotension appears to be mediated by adenosine A₁receptors and results primarily from increased outflow facility.